Sensitization of neuroblastoma cells for TRAIL‐induced apoptosis by NF‐κB inhibition

The transcription factor nuclear factor‐kappaB (NF‐κB) plays a central role in stress‐induced transcriptional activation and has been implicated in chemoresistance of cancers. In the present study, we investigated the role of NF‐κB in inducible chemoresistance of neuroblastoma. Doxorubicin, VP16 and the cytotoxic ligand TRAIL trigger NF‐κB activation, whereas cisplatin and taxol have no impact on NF‐κB activity. Specific inhibition of NF‐κB activation by overexpression of dominant‐negative mutant IκBα‐super‐repressor does not alter cell death upon doxorubicin or VP16 treatment, although it prevents doxorubicin‐ or VP16‐mediated NF‐κB activation. By comparison, inhibition of TRAIL‐stimulated NF‐κB activation by IκBα‐superrepressor or the small molecule NF‐κB inhibitor BMS‐345541 significantly enhances TRAIL‐induced apoptosis, pointing to an antiapoptotic function of NF‐κB in TRAIL‐mediated apoptosis. Analysis of signaling pathways reveals that NF‐κB inhibition prevents TRAIL‐triggered up‐regulation of Mcl‐1, promoting TRAIL‐induced cytochrome c release and activation of caspases. Accordingly, knockdown of Mcl‐1 by RNA interference significantly enhances TRAIL‐induced apoptosis and also increases sensitivity of neuroblastoma cells to CD95‐ or chemotherapy‐induced apoptosis. In conclusion, NF‐κB regulates apoptosis in a stimulus‐specific manner in neuroblastoma cells and confers protection against TRAIL‐induced apoptosis. By demonstrating that NF‐κB inhibition sensitizes neuroblastoma cells for TRAIL‐induced apoptosis, our findings have important implications. Thus, NF‐κB inhibitors may open new perspectives to potentiate the efficacy of TRAIL‐based protocols in the treatment of neuroblastoma. © 2008 Wiley‐Liss, Inc.

[1]  S. Fulda,et al.  Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells , 2007, Oncogene.

[2]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[3]  B. Dörken,et al.  Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. , 2001, Blood.

[4]  Huey-Jen Lin,et al.  Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas Stimulation* , 2004, Journal of Biological Chemistry.

[5]  S. Fulda,et al.  Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.

[6]  E. D. de Vries,et al.  The clinical trail of TRAIL. , 2006, European journal of cancer.

[7]  E. Feldman,et al.  Insulin-like Growth Factor I Prevents Mannitol-induced Degradation of Focal Adhesion Kinase and Akt* , 2002, The Journal of Biological Chemistry.

[8]  F. Berthold,et al.  Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. , 2000, Drugs.

[9]  S. Fulda,et al.  Modulation of TRAIL signaling for cancer therapy. , 2004, Vitamins and hormones.

[10]  J. Clohessy,et al.  Mcl-1 Interacts with Truncated Bid and Inhibits Its Induction of Cytochrome c Release and Its Role in Receptor-mediated Apoptosis* , 2006, Journal of Biological Chemistry.

[11]  H. Kalthoff,et al.  CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells , 2001, Oncogene.

[12]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[13]  K. McIntyre,et al.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. , 2003, The Journal of biological chemistry.

[14]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[15]  K. Flaherty,et al.  Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. , 2007, Cancer cell.

[16]  N. Perkins,et al.  Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. , 2006, Cancer research.

[17]  S. Fulda,et al.  Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol , 2004, Cancer Research.

[18]  N. Perkins,et al.  Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. , 2004, Molecular cell.

[19]  M. Corazzari,et al.  The NF-kappaB pathway mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells. , 2005, Apoptosis : an international journal on programmed cell death.

[20]  P. Vandenabeele,et al.  Toxic proteins released from mitochondria in cell death , 2004, Oncogene.

[21]  B. Gastman,et al.  Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis* , 2006, Journal of Biological Chemistry.

[22]  Michael Karin,et al.  The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.

[23]  I. Herr,et al.  Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .

[24]  Céline Gélinas,et al.  To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. , 2003, Oncogene.

[25]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[26]  K. Debatin,et al.  A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release , 2004, Cell Death and Differentiation.

[27]  M. Peter,et al.  Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. , 1997, Cancer research.

[28]  N. Perkins,et al.  Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB , 2004 .

[29]  W. London,et al.  Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. El-Deiry,et al.  Mcl-1: a gateway to TRAIL sensitization. , 2008, Cancer research.

[31]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[32]  T. Wirth,et al.  Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. , 2001, The Journal of biological chemistry.

[33]  M. Corazzari,et al.  The NF-κB pathway mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells , 2005, Apoptosis.

[34]  C. Gélinas,et al.  To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis , 2003, Oncogene.

[35]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[36]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[37]  E. Henson,et al.  Increased expression of Mcl‐1 is responsible for the blockage of TRAIL‐induced apoptosis mediated by EGF/ErbB1 signaling pathway , 2003, Journal of cellular biochemistry.

[38]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[39]  N. Perkins,et al.  Differential regulation of NF-κB activation and function by topoisomerase II inhibitors , 2006, BMC Cancer.

[40]  T. Wirth,et al.  Activation of NF-κB via the IκB Kinase Complex Is Both Essential and Sufficient for Proinflammatory Gene Expression in Primary Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[41]  I. Chang,et al.  Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. , 2005, Cancer research.

[42]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[43]  David Loegering,et al.  MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis , 2007, Journal of Biological Chemistry.

[44]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[45]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[46]  J. Piette,et al.  Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. , 1996, Nucleic acids research.

[47]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[48]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[49]  J. Cusack,et al.  Potentiation of Chemotherapeutic Agents following Antagonism of Nuclear Factor kappa B in Human Gliomas , 2003, Journal of Neuro-Oncology.

[50]  N. Perkins,et al.  Good cop, bad cop: the different faces of NF-κB , 2006, Cell Death and Differentiation.

[51]  S. Fulda,et al.  Betulinic acid as new activator of NF-κB: molecular mechanisms and implications for cancer therapy , 2005, Oncogene.

[52]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[53]  C. Y. Wang,et al.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.

[54]  N. Perkins,et al.  Good cop, bad cop: the different faces of NF-kappaB. , 2006, Cell death and differentiation.

[55]  M. Merville,et al.  Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. , 1999, Cancer research.